Beyond anti-VEGF: can faricimab reduce treatment burden for retinal disease?

Lancet. 2022 Feb 19;399(10326):697-699. doi: 10.1016/S0140-6736(22)00105-2. Epub 2022 Jan 24.
No abstract available

Publication types

  • Comment

MeSH terms

  • Angiogenesis Inhibitors* / therapeutic use
  • Humans
  • Ranibizumab / therapeutic use
  • Retinal Diseases* / drug therapy

Substances

  • Angiogenesis Inhibitors
  • Ranibizumab